image credit- shutterstock
Alloy Therapeutics Co. has announced the signing of a Memorandum of Understanding (MoU) with the Kansai Startup Academia Coalition (KSAC), represented by Kyoto University, to foster the global expansion of university-affiliated life science startups across Japan.
This strategic collaboration is designed to accelerate research and development (R&D) activities by providing critical support and connecting academic innovations with the global biopharmaceutical industry.
KSAC is a coalition of more than 90 academic institutions located in western Japan, formed under the leadership of Kyoto University and with support from Japan’s Ministry of Education, Culture, Sports, Science and Technology (MEXT). KSAC’s mission is to bridge academia and industry by managing GAP funds for research, delivering entrepreneurship education, supporting digital workshop networks, and showcasing early-stage technologies through events and exhibitions both domestically and internationally.
Alloy Therapeutics Inc. is a Boston-based biotechnology ecosystem company that democratises access to foundational biologics discovery technologies. Through its suite of platform technologies and discovery services as well as its venture studio, 82VS, Alloy enables scientists and entrepreneurs around the world to accelerate the discovery of medicines. Alloy recently launched its Japan subsidiary, Alloy Japan, which is focused on iPS cell therapy development and is continuing to broaden its offerings by supporting ecosystem growth throughout Japan and greater Asia.
Through this MoU, Alloy Japan and KSAC will collaborate to connect promising academic seeds from Japan to global Biopharma markets, while also bringing valuable insights from the global community back to strengthen Japan’s startup ecosystem. Together, they aim to enrich critical capabilities across Japan’s academic and entrepreneurial communities to foster the development of globally competitive life science startups.
